Today's edition of the NCI Cancer Bulletin features another natural product clinical trial, this time for depsipeptide in T-cell lymphoma.
Depsipeptide (Romidepsin or FR901228) is an early histone deacetylase inhibitor isolated from fermentation of Chromobacterium violaceum. Several histone deacetylase inhibitors are in clinical trials for various cancers and many are derived from natural products. However, the first HDAC inhibitor approved by FDA is a synthetic compound, SAHA or vorinostat (Zolinza), also for T-cell lymphoma.
What is it about T-cell lymphoma that attracts the development of HDAC inhibitors??? Hmmm.
- Log in to post comments
More like this
SAHA, or suberoylanilide hydroxamic acid, was recently granted orphan drug approval by the US FDA for skin lesions resulting from cutaneous T-cell lymphoma.
SAHA (vorinostat, Zolinza) will be marketed by Merck as they acquired in 2004 Aton Pharma, who had been developing the compound. (This free…
Over the last couple of weeks, I've been spending a lot of time (and, characteristically, verbiage) analyzing the phenomenon known as Dr. Stanislaw Burzynski, his "cancer cure" known as antineoplastons, and his incompetent version of "personalized gene-targeted cancer therapy." In this third and…
Note: Orac is away somewhere warm recharging his Tarial cells for further science and skepticism. In the meantime, he is rerunning some of his favorite posts. Given that the blog seems to have been infiltrated with Burzynski trolls again and Eric Merola threatens to make a sequel to the execrable…
Last week, I applied a little not-so-Respectful Insolence to a movie about a physician and "researcher" named Stanislaw Burzynski, MD, PhD, founder of the Burzynski Clinic and Burzynski Research Institute in Houston. I refer you to my original smackdown for details, but in brief Dr. Burzynski…
What is it about T-cell lymphoma that attracts the development of HDAC inhibitors???
Blood cell tumors typically require 2-3 fewer molecular events to progress to malignancy, probably in large part because they do not need to acquire invasiveness/vascularization potential. Such tumors are therefore potentially more dependent on the few molecular alterations they have than are more complex tumors. Upregulation or dysregulation of HDAC activity is a common step in many tumorigenic pathways -- it's more or less a generic "pro-proliferative" event, driving cells to replicate.
So, my guess -- and I do mean guess -- is that lymphomas are no more likely than other cancers to have HDAC up/dysregulation in their sordid past, but they are more likely to be dependent on it and vulnerable at that single point of inhibitor action.
Oops:
...fewer molecular events than solid tumors to progress...
Oops again -- HDACs are typically recruited by repressors, not activators. I got HDACs and histone acetyltransferases the wrong way around; I'm always doing that.
When HDACs are involved in cancer, I think the supposition is that inappropriate deacetylation (silencing) of tumor suppressor genes is involved. So, with that change, I think my guess stands.